REGENTIS BIOMATERIALS LTD. (RGNT)
US Markets · Healthcare · Medical - Instruments & Supplies
$1.50
-21.05%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$10.2M
About REGENTIS BIOMATERIALS LTD.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.